PUBLIC COMPANY

$RCKTROCKET PHARMACEUTICALS, INC.

New York, NY, USupdated 1mo ago

SEC EDGAR Yahoo Finance

community read0 votes

pipeline

4

marketed

1

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(4)

pipeline depth4 products

2Phase 11Phase 21Marketed

Marketed

marnetegragene autotemcel

Leukocyte Disorders (White Blood Cell Disorders)

Phase 2

RPA-501

Glycogen Storage Disease (GSD)

Dilated Cardiomyopathy

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view ROCKET PHARMACEUTICALS, INC. jobs →

News

no news has mentioned this company yet

$RCKT

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

SEC EDGAR

last refreshed 1m ago

Found something off?

Active trials

phase2A Gene Therapy Study of RP-A501 in Male Patients With Danon Diseaserecruitingn=14
phase2Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiencysuspendedn=10
phase1A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)recruitingn=9
—Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the Infusion of RP-L102enrolling by invitationn=14
—Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapyactive not recruitingn=9
—Danon Disease Natural History Studyrecruitingn=60
phase1A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathyrecruitingn=8
—BAG3-DCM Natural History Studynot yet recruitingn=30

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 18, 26SELLShah Gaurav· CEO5,990 sh @ $3.34−$20K↗
Feb 18, 26SELLWilson Martin· General Counsel1,376 sh @ $3.34−$5K↗
Feb 18, 26SELLMilitello John· See Remarks1,157 sh @ $3.34−$4K↗
Feb 13, 26SELLShah Gaurav· CEO12,279 sh @ $3.31−$41K↗
Feb 13, 26SELLWilson Martin· General Counsel12,253 sh @ $3.31−$41K↗
Feb 13, 26SELLMilitello John· See Remarks3,726 sh @ $3.31−$12K↗

routine RSU / option mechanics (6)

Feb 11, 26grantWilson Martin · General Counsel468,187 sh
Feb 11, 26grantRizvi Syed Ali-aamir · Chief Medical Officer61,963 sh
Feb 11, 26grantRizvi Syed Ali-aamir · Chief Medical Officer93,037 sh
Feb 11, 26grantStevens Christopher James · Chief Operating Officer61,963 sh
Feb 11, 26grantStevens Christopher James · Chief Operating Officer93,037 sh

Feb 11, 26

grant

Chaudhuri Sarbani · See Remarks

125,924 sh